Antimony Trisulfide Benzoic Acid Ledum Palustre Tw

證據等級: L5

預測適應症: 0 個

Multi-Component Homeopathic Combination: Insufficient Data for Repurposing Evaluation

One-Sentence Summary

This Evidence Pack contains a seven-component combination product (including Antimony Trisulfide, Benzoic Acid, Ledum Palustre, Quercus Robur, Rhododendron Aureum, Silicon Dioxide, and Strychnos Nux-Vomica) that appears to be a homeopathic formulation. The TxGNN model returned no predicted indications for this submission, and no original indications, regulatory approvals, or safety records were identified. Without a valid DrugBank ID or recognized active pharmaceutical ingredient mapping, this candidate cannot be assessed under the standard repurposing framework.

Quick Overview

Item	Content
Original Indication	Not available
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	Below L5 (no predictions, no studies identified)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

The TxGNN model relies on mapping submitted drug names to DrugBank IDs, which are then located within a biomedical knowledge graph to generate disease predictions. This submission failed to complete that pipeline for the following reasons:

1. No DrugBank ID resolved. The submitted string is a semicolon-delimited list of seven ingredients — none of which resolved to a single DrugBank entry. TxGNN requires a unique, mappable compound node to traverse the knowledge graph.

2. Homeopathic and botanical components. Several ingredients (Ledum palustre twig, Quercus robur flower, Rhododendron aureum leaf, Strychnos nux-vomica seed) are classical homeopathic remedies used in highly diluted form. These substances are not represented as standard pharmacological nodes in the TxGNN knowledge graph, which is built on conventional drug–disease relationships.

3. Inactive and excipient components. Silicon dioxide is a pharmaceutical excipient with no therapeutic target. Benzoic acid at typical formulation concentrations is an antimicrobial preservative, not a primary active ingredient. Including these alongside botanical materials further prevents clean ingredient-level mapping.

4. No original indication to anchor repurposing logic. The standard repurposing evaluation asks: “given this drug’s proven efficacy in Indication A, can the same mechanism explain efficacy in Indication B?” Without a validated original indication, this reasoning chain cannot begin.

Conclusion and Next Steps

Decision: Hold

Rationale: This submission cannot enter the TxGNN repurposing pipeline as currently structured. The product appears to be a multi-ingredient homeopathic preparation with no DrugBank representation, no regulatory approval in any surveyed jurisdiction, and no clinical evidence base. The TxGNN model returned zero predicted indications, making downstream evaluation impossible.

To proceed, the following is needed:

Clarify the intended active ingredient. If one specific component (e.g., Nux vomica alkaloids, antimony compounds) is the therapeutic focus, resubmit with that single ingredient’s INN and obtain its DrugBank ID.
Confirm product category. If this is a registered homeopathic product in any country, provide the relevant national registry number so regulatory context can be established.
Obtain MOA documentation. If a plausible pharmacological mechanism exists for any component, provide the source (DrugBank, peer-reviewed literature) so TxGNN graph traversal can be attempted manually.
Verify market status. Query the originating country’s drug registry (e.g., Taiwan TFDA, EU HMPC, US HHS/FDA homeopathic listings) to confirm whether any license has ever been issued for this combination.
Safety assessment prerequisite. If this product contains Strychnos nux-vomica at a non-homeopathic (pharmacologically active) dose, strychnine toxicity data must be reviewed before any repurposing discussion proceeds. This is a safety blocker regardless of indication.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.